Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regulus Therapeutics

2.32
+0.310015.42%
Pre-market: 2.350.0300+1.29%05:59 EDT
Volume:1.57M
Turnover:3.56M
Market Cap:153.68M
PE:-2.82
High:2.33
Open:2.04
Low:2.01
Close:2.01
Loading ...

Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit

PR Newswire
·
02 Apr

Oppenheimer Reaffirms Their Buy Rating on Regulus (RGLS)

TIPRANKS
·
28 Mar

Regulus Therapeutics Inc : Wells Fargo Raises to Overweight From Equal Weight; Raises Target Price to $6 From $3

THOMSON REUTERS
·
28 Mar

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live
·
28 Mar

Regulus Therapeutics Raised to Overweight From Equal-Weight by Wells Fargo

Dow Jones
·
28 Mar

Wells Fargo Upgrades Regulus Therapeutics to Overweight From Equalweight, $6 Price Target; Share Rise

MT Newswires Live
·
28 Mar

Regulus Therapeutics Completes Phase 1b Farabursen Study in Polycystic Kidney Disease

MT Newswires Live
·
28 Mar

BRIEF-Regulus Completes Phase 1B Trial Of Farabursen For Autosomal Dominant Polycystic Kidney Disease

Reuters
·
27 Mar

Regulus Therapeutics Inc -Positive Topline Data From Fourth Cohort of Patients

THOMSON REUTERS
·
27 Mar

Regulus Therapeutics Inc -on Track for Initiation of Phase 3 Single Pivotal Trial in Q3 2025

THOMSON REUTERS
·
27 Mar

Regulus Therapeutics-Patients Receiving 300 Mg Farabursen Demonstrated Mean Halting of Height-Adjusted Total Kidney Volume Growth Over 4 Months

THOMSON REUTERS
·
27 Mar

Regulus Therapeutics Announces Successful Completion of Its Phase 1B Multiple-Ascending Dose (Mad) Clinical Trial of Farabursen (Rgls8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (Adpkd)

THOMSON REUTERS
·
27 Mar

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PR Newswire
·
27 Mar

Regulus Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
17 Mar

Promising Developments and Strategic Positioning Drive Buy Rating for Regulus Therapeutics

TIPRANKS
·
17 Mar

Is Regulus Therapeutics (NASDAQ:RGLS) In A Good Position To Invest In Growth?

Simply Wall St.
·
15 Mar

Regulus Therapeutics Reports Positive Trial Results and Financials

TIPRANKS
·
15 Mar

Regulus Therapeutics Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Mar

Regulus Therapeutics Q4 Operating Expenses USD 13.746 Million

Reuters
·
14 Mar

Regulus: Q4 Earnings Snapshot

Associated Press Finance
·
14 Mar